JP2024527235A5 - - Google Patents
Info
- Publication number
- JP2024527235A5 JP2024527235A5 JP2023574356A JP2023574356A JP2024527235A5 JP 2024527235 A5 JP2024527235 A5 JP 2024527235A5 JP 2023574356 A JP2023574356 A JP 2023574356A JP 2023574356 A JP2023574356 A JP 2023574356A JP 2024527235 A5 JP2024527235 A5 JP 2024527235A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163213478P | 2021-06-22 | 2021-06-22 | |
| US63/213,478 | 2021-06-22 | ||
| US202163242929P | 2021-09-10 | 2021-09-10 | |
| US63/242,929 | 2021-09-10 | ||
| PCT/US2022/034373 WO2022271722A1 (en) | 2021-06-22 | 2022-06-21 | Anti-egfrviii antibody drug conjugates and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527235A JP2024527235A (ja) | 2024-07-24 |
| JP2024527235A5 true JP2024527235A5 (cg-RX-API-DMAC10.html) | 2025-06-25 |
Family
ID=82655068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574356A Pending JP2024527235A (ja) | 2021-06-22 | 2022-06-21 | 抗EGFRvIII抗体薬物コンジュゲート及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240293566A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4359440A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024527235A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240024061A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022298653A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3212850A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL309048A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023014683A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022271722A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4653017A1 (en) | 2023-01-18 | 2025-11-26 | Tyligand Bioscience (Shanghai) Limited | Antibody-drug conjugate and use thereof |
| WO2025148868A1 (zh) | 2024-01-08 | 2025-07-17 | 泰励生物科技(上海)有限公司 | 一种抗体偶联药物及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE69025946T2 (de) | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| DK1392359T4 (da) | 2001-05-11 | 2013-06-10 | Ludwig Inst For Cancer Res Ltd | Specifikke bindingsproteiner og deres anvendelser. |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| MXPA05014155A (es) | 2003-06-27 | 2006-05-25 | Abgenix Inc | Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos. |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| DK2808393T3 (en) | 2009-06-02 | 2018-03-12 | Regeneron Pharma | Cells insufficient for fucosylation |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| EP3964237B1 (en) * | 2013-03-15 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| AU2015229591B2 (en) * | 2014-03-11 | 2020-10-22 | Regeneron Pharmaceuticals, Inc. | Anti-EGFRvlll antibodies and uses thereof |
| CN116059201A (zh) * | 2016-06-08 | 2023-05-05 | 艾伯维公司 | 抗egfr抗体药物偶联物 |
| CN109562190A (zh) * | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗egfr抗体药物偶联物 |
-
2022
- 2022-06-21 JP JP2023574356A patent/JP2024527235A/ja active Pending
- 2022-06-21 AU AU2022298653A patent/AU2022298653A1/en active Pending
- 2022-06-21 CA CA3212850A patent/CA3212850A1/en active Pending
- 2022-06-21 WO PCT/US2022/034373 patent/WO2022271722A1/en not_active Ceased
- 2022-06-21 MX MX2023014683A patent/MX2023014683A/es unknown
- 2022-06-21 EP EP22744564.0A patent/EP4359440A1/en active Pending
- 2022-06-21 KR KR1020237041451A patent/KR20240024061A/ko active Pending
- 2022-06-21 US US18/572,930 patent/US20240293566A1/en active Pending
- 2022-06-21 IL IL309048A patent/IL309048A/en unknown